Key result
Infusion of rt-PA induced coronary thrombolysis in 83% of patients with evolving myocardial infarction, with a plasma half-life of approximately 9 minutes.
Why the study?
What are the pharmacokinetic properties and thrombolytic effects of rt-PA in patients with evolving myocardial infarction?
Population
12 patients with evolving myocardial infarction treated for coronary thrombosis
Design
Case_series
Authors
Loading...
Hypothesis-generating for rt-PA in evolving MI; larger randomized trials needed before clinical adoption.
What are the pharmacokinetic properties and thrombolytic effects of rt-PA in patients with evolving myocardial infarction?
rt-PA infusion in patients with evolving myocardial infarction achieves rapid, dose-proportional peak plasma levels with a short half-life and effectively induces coronary thrombolysis.
Robinson et al. (1985) studied evolving myocardial infarction (n=12). tissue-type plasminogen activator (rt-PA) was evaluated on coronary thrombolysis. Infusion of rt-PA induced coronary thrombolysis in 83% of patients with evolving myocardial infarction, with a plasma half-life of approximately 9 minutes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: